Vistin Pharma ASA · OSL:VISTN
Vistin Pharma ASA — Investor Presentation (October 2016)
22 slides from Vistin Pharma ASA's investor presentation, October 2016
Slide 1: Vistin Pharma – Corporate Presentation
Vistin Pharma – Corporate Presentation October 2016
Slide 2: Content
Content Introduction to Vistin Pharma Operational and financial update Summary & outlook Appendix
Slide 3: Snapshot: Vistin at a glance
Snapshot Vistin at a glance Summary Presence in c.40 countries Established in June 2015, when the company was spun off from Weifa and listed on the Oslo Axess stock exchange Norway Leading producer of active ingredients (API) and finished products for diabetes medicine (metformin) and opiates fo
Slide 4: Vistin's key milestones
Vistin’s key milestones Long and successful track record of producing high quality APIs and FDFs Vistin’s evolution Weifa Vistin Pharma 1940: 1952: 1969: 1986: 2014: 2015: Weiders First Launch of Production Codeine Vistin Pharma Farmasoytiske production metformin API start of Ibux tablets added esta
Slide 5: Content
Content Introduction to Vistin Pharma Operational and financial update Summary & outlook Appendix
Slide 6: Vistin – a leading producer of high quality metformin
Vistin – a leading producer of high quality metformin First line treatment for type 2 diabetes Fully integrated metformin supplier One of the few European manufacturers of metformin HCl Producer of three different types of metformin products: Leading independent producer Global manufacturing capacit
Slide 7: Diabetes - a global epidemic
Diabetes - a global epidemic Type 2 diabetes is one of the greatest challenges to healthcare systems around the world – and metformin is expected to maintain its position as the gold standard treatment in the foreseeable future Estimated global growth in diabetes 387 million people live with Growt
Slide 8: Significant upside from additional capacity expansion
Significant upside from additional capacity expansion Vistin plans to capitalise on strong demand in its metformin business by doubling the capacity at its plant in Kragerø Summary Significant long term growth in the metformin market and increased demand from Vistin’s customers – Forecast volumes
Slide 9: Vistin – a major opioids "powder-to-pill" supplier
Vistin – a major opioids “powder-to-pill” supplier The company supplies c.6% of the global market for codeine API, a very commonly used medicinal opioid Overview Leading independent manufacturer of opioids Vistin produces two APIs in the opioid sector Codeine market Pholcodine market – Codeine (used
Slide 10: Opioids market overview
Opioids market overview A protected market with high entry barriers Key features of the opioids market Strong growth in global opioids consumption 1Strong growth in global opioids consumption A protected business owing to tight controls by the 14 International Narcotics Control Board (INCB) and th
Slide 11: Vistin – A leading CMO tablet manufacturer
Vistin – A leading CMO tablet manufacturer Current annual production of c.750 million tablets with potential to expand capacity Significant tablet manufacturer Summary of Weifa contract Manufacture of tablets relating to opioids and metformin business and reported as part of B2B segment CMO agre
Slide 12: State of the art manufacturing facilities
State of the art manufacturing facilities Well invested plants with potential for further expansion Fikkjebakke manufacturing site Gruveveien manufacturing site Fikkjebakke is dedicated to the production of metformin HCl and metformin DC Gruveveien produces Solid Dosage Forms (SDF) and opioids API's
Slide 13: Financial overview
Financial overview Strong financial growth profile with significant potential upside through capacity expansion Revenue evolution (2011–1H2016 NOKm)1 376 118 242 229 213 199 170 61 258 229 242 199 170 152 2011 2012 2013 2014 2015 6M 2016 B2B CMO Notes 1 Revenue figures for 2011 – 2014 are for B2B se
Slide 14: Content
Content Introduction to Vistin Pharma Operational and financial update Summary & outlook Appendix
Slide 15: Key investment highlights
Key investment highlights Leading producer of high quality APIs and Solid Dosage Forms 1 Leading Producer: Amongst Top 5 producers of metformin HCl globally and largest 7 independent producer of Codeine 2 Phosphate High Quality Reputation: Strong Leadership: Leading reputation as producer of Experie
Slide 16: Summary & outlook
Summary & outlook Metformin: Strong performance and bright outlook Continued strong growth expected Doubled capacity from 2019 NOK 120 million investment to be financed through existing cash reserves, cash flow generation and debt Opioids: Long-term drivers indicating attractive future growth
Slide 17: Content
Content Introduction to Vistin Pharma Operational and financial update Summary & outlook Appendix
Slide 18: Consolidated income statement as of June 2016
Consolidated income statement as of 30 June 20161 (figures for 2015 reflect Vistin Pharma’s business operations from 1 June 2015) (NOK 1 000) Q2 2016 Q2 2015 YTD2016 YTD2015 FY 2015 Total revenue and income 109 667 31 370 212 893 31 370 227 892 EBITDA 12 608 2 862 23 639 2 862 27 883 Depreciation, a
Slide 19: Financial position as of June 2016
Financial position as of 30 June 2016 (NOK 1 000) 30.06.2016 30.06.2015 31.12.2015 Property, plant & equipment 46 275 33 275 41 331 Inventory 86 156 91 015 92 712 Trade receivables 64 240 33 197 54 760 Cash & cash equivalents 55 710 44 558 61 989 Other 7 630 19 372 8 216 Total Assets 260 011 221 417
Slide 20: Experienced management team
Experienced management team Highly experienced management team with a strong industry track record Name Role Experience Previous experience includes several years in top management positions at Alpharma, Chief Executive a leading international generic pharmaceutical company Kjell-Erik Nordby Offic
Slide 21: Top shareholders as of September 2016
Top 20 shareholders as of 30 September 2016 NAME SHAREHOLDING % SHARE EUROCLEAR BANK S.A. 2 548 810 14,9% STRATA MARINE & OFFSHORE* 1 965 943 11,5% STOREBRAND VEKST 1 395 460 8,2% MP PENSJON PK 877 870 5,1% SOLAN CAPITAL AS 787 482 4,6% SKANDINAVISKE ENSKILDA 779 352 4,6% FERNCLIFF LISTED DAI* 582 2
Slide 22: Disclaimer
Disclaimer This Presentation has been produced by Vistin Pharma ASA (the “Company” or “Vistin Pharma ”) solely for use at the presentation to investors and other stake holders and may not be reproduced or redistributed, in whole or in part, to any other person. This presentation has not been revie